We are live on
!
Find out more
AIC
Argus Investors Counsel Portfolio holdings
AUM
$130M
1-Year Est. Return
37.06%
This Fund
S&P 500
This Quarter
Est. Return
+2.98%
1 Year Est. Return
+37.06%
3 Year Est. Return
+123.69%
5 Year Est. Return
+149.89%
10 Year Est. Return
+466.25%
AUM
$150M
AUM Growth
-$3.53M
(-2.3%)
Cap. Flow
-$5.49M
Cap. Flow
% of AUM
-3.67%
Top 10 Holdings %
Top 10 Hldgs %
29.01%
Holding
118
New
7
Increased
28
Reduced
76
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BNY
Bank of New York Mellon
BNY
|
+$588K |
| 2 |
Invesco S&P 500 Quality ETF
SPHQ
|
+$438K |
| 3 |
Phillips 66
PSX
|
+$249K |
| 4 |
GE HealthCare
GEHC
|
+$244K |
| 5 |
Dick's Sporting Goods
DKS
|
+$236K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$822K |
| 2 |
Pfizer
PFE
|
+$809K |
| 3 |
Morgan Stanley
MS
|
+$283K |
| 4 |
JPMorgan Chase
JPM
|
+$279K |
| 5 |
Netflix
NFLX
|
+$276K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.61% |
| 2 | Financials | 17.16% |
| 3 | Healthcare | 14.32% |
| 4 | Industrials | 13.86% |
| 5 | Communication Services | 7.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
American Express
AXP
$229B
| $2M | 1.33% |
6,722
-434
| -6% | -$125K |
|
27
Stryker
SYK
$133B
| $1.9M | 1.27% |
5,272
-469
| -8% | -$174K |
|
|
28
McKesson
MCK
$103B
| $1.77M | 1.18% |
3,103
-1,467
| -32% | -$822K |
|
29
Home Depot
HD
$350B
| $1.73M | 1.16% |
4,454
-466
| -9% | -$190K |
|
30
Salesforce
CRM
$162B
| $1.58M | 1.05% |
4,712
-52
| -1% | -$16.6K |
|
31
Thermo Fisher Scientific
TMO
$222B
| $1.56M | 1.04% |
2,995
-38
| -1% | -$20.9K |
|
32
ExxonMobil
XOM
$657B
| $1.53M | 1.02% |
14,200
-1,217
| -8% | -$142K |
|
33
Applied Materials
AMAT
$415B
| $1.47M | 0.98% |
9,036
-124
| -1% | -$22.5K |
|
|
34
Netflix
NFLX
$318B
| $1.41M | 0.94% |
15,840
-3,350
| -17% | -$276K |
|
35
Microchip Technology
MCHP
$44.2B
| $1.39M | 0.93% |
24,170
-672
| -3% | -$46.2K |
|
36
Regeneron Pharmaceuticals
REGN
$83.2B
| $1.3M | 0.87% |
1,820
-21
| -1% | -$17.6K |
|
37
Walmart Inc
WMT
$897B
| $1.27M | 0.85% |
14,064
-2,200
| -14% | -$191K |
|
38
iShares Russell 1000 Growth ETF
IWF
$127B
| $1.26M | 0.84% |
12,508
+324
| +3% | +$31.9K |
|
39
Procter & Gamble
PG
$340B
| $1.15M | 0.76% |
6,830
-609
| -8% | -$104K |
|
40
Marriott International
MAR
$90.9B
| $1.13M | 0.75% |
4,039
-475
| -11% | -$130K |
|
41
Chevron
CVX
$382B
| $1.12M | 0.75% |
7,731
-120
| -2% | -$18.4K |
|
42
Mastercard
MA
$493B
| $1.11M | 0.74% |
2,108
-20
| -0.9% | -$10.4K |
|
43
Automatic Data Processing
ADP
$109B
| $1.06M | 0.71% |
3,627
-77
| -2% | -$22.8K |
|
44
US Bancorp
USB
$100B
| $996K | 0.67% |
20,833
-2,500
| -11% | -$123K |
|
45
Corning
GLW
$136B
| $995K | 0.66% |
20,935
-4,000
| -16% | -$189K |
|
46
Johnson & Johnson
JNJ
$631B
| $976K | 0.65% |
6,746
-55
| -0.8% | -$8.52K |
|
47
Union Pacific
UNP
$174B
| $971K | 0.65% |
4,256
-496
| -10% | -$117K |
|
48
Amgen
AMGN
$226B
| $958K | 0.64% |
3,674
-152
| -4% | -$45.1K |
|
49
Verizon
VZ
$195B
| $957K | 0.64% |
23,942
-2,850
| -11% | -$120K |
|
50
TJX Companies
TJX
$175B
| $956K | 0.64% |
7,915
-1,200
| -13% | -$143K |
|
Similar funds
NCM
CG
EPCA
WM
BM
EPI
OIM
ECP
Argus Investors Counsel's Q4 2024 Portfolio in Review
As of Q4 2024, Argus Investors Counsel held 118 positions worth $150M, down 2.3% from $153M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Argus Investors Counsel withdrew a net $5.49M in Q4 2024, closing 1 position and reducing 76 holdings. Its most notable exit was Pfizer, an estimated $809K position sold in full.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Argus Investors Counsel opened a new position in Bank of New York Mellon worth $584K.
- Argus Investors Counsel's largest Q4 2024 buy was Bank of New York Mellon: 7,602 shares worth $584K.
- Argus Investors Counsel added most to iShares MSCI EAFE ETF in Q4 2024, an estimated $161K increase.
- Argus Investors Counsel's biggest Q4 2024 reduction was McKesson, cutting an estimated $822K.
- Argus Investors Counsel fully exited Pfizer in Q4 2024, selling an estimated $809K.
- Argus Investors Counsel's ten largest holdings make up 29% of its $150M portfolio in Q4 2024.
- Argus Investors Counsel opened 7 new positions and closed 1 in Q4 2024.
- Argus Investors Counsel's portfolio value fell 2.3% quarter-over-quarter to $150M.
Based on Argus Investors Counsel's 13F filing for Q4 2024, filed 27 Jan 2025.